Zeto Announces Winners of Clinical Trial Sponsorship Program
SANTA CLARA, Calif., June 25, 2024 /PRNewswire/ -- Zeto, Inc., an award-winning medical technology firm, is proud to announce the...
Diagnostics
Prospective Trial Shows Impact of Home OCT Guided Wet AMD Patient Management
Remote monitoring reduces office visit and treatment burden in some patientsManassas, Virginia--(Newsfile Corp. - June 25, 2024) - Digital healthcare...
GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease
Results from commercial sales of predictive testing across the US and Australia establish clear advantages of geneType Risk Assessment Tests...
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ:...
Insider Information: Nexstim Plc’s offering for an EUR 750,000 convertible bond has closed and EUR 650,000 of the bond was subscribed for
Company Announcement, Helsinki, 25 June 2024 at 9:30 AM (EEST) Insider Information: Nexstim Plc’s offering for an EUR 750,000 convertible...
Insider Information: Nexstim Plc launches an unsecured convertible bond offering of up to EUR 750,000
Company Announcement, Helsinki, 25 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc launches an unsecured convertible bond offering...
Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV)...
Danaher Schedules Second Quarter 2024 Earnings Conference Call
WASHINGTON, June 24, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for...
Artificial Intelligence (AI) in Healthcare Market to Grow at 38.2% CAGR by 2031 | SkyQuest Technology
WESTFORD, Mass., June 24, 2024 /PRNewswire/ -- As per SkyQuest, the Global Artificial Intelligence in Healthcare Market size was valued at USD...
Thermal Cyclers Market Worth 1.86 Billion 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
JERSEY CITY, N.J., June 24, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report...
Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27
CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic...
Gemina Laboratories Commences Trading on the OTCQB Market in the United States
Gemina Laboratories (OTCQB: GLABF), (CSE: GLAB), (FRA: 817) expands investor reach to U.S. by posting shares on OTCQB. VANCOUVER, BC...
GE HealthCare and MediView Announce the World’s First Installation and Clinical Use of Augmented Reality Interventional Suite that Aims to Transform the Practice of Interventional Radiology
GE HealthCare and MediView XR, Inc. announce the first installation and clinical use of augmented reality solution OmnifyXR Interventional Suite...
Aidoc’s New AI Patient Management Technology Boosts Clinic Volumes and Elevates Patient Care
Yale New Haven Health unveils impact data during the 2024 Vascular Annual Meeting (VAM), showing Aidoc AI's ability to support...
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT...
Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer
SAN DIEGO--(BUSINESS WIRE)--#TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment...
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure...
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path),...
AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD
The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s...
Lupus Research Alliance Awards Lupus Insight Prize to Two Trailblazers in CAR T Cell Therapy
Drs. Marko Radic and Georg Schett Honored at FOCIS 2024 Meeting SAN FRANCISCO, June 20, 2024 /PRNewswire/ -- The Lupus...